Pin1-Nanog expression in human glioma is correlated with advanced tumor progression

Oncology Reports

Volumn 30, Issue 2, 2013, Pages 560-566

  Yang, Yang ^a,b   Niu, Chao Shi ^a,b,c   Cheng, Chuan Dong ^a,b  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b University of Science and Technology of China   (China)

^c Anhui Provincial Stereotactic Neurosurgical Institute   (China)

Author keywords

Expression; Glioma; Naog; Pin1

Indexed keywords

MESSENGER RNA; PEPTIDYLPROLYL ISOMERASE PIN1; TRANSCRIPTION FACTOR NANOG;

ADVANCED CANCER; ARTICLE; CANCER GRADING; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; GENE EXPRESSION; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; PERINUCLEAR SPACE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

CELL LINE, TUMOR; CYTOPLASM; DISEASE PROGRESSION; GLIOMA; HOMEODOMAIN PROTEINS; HUMANS; PEPTIDYLPROLYL ISOMERASE; RNA, MESSENGER;

EID: 84879651909     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2481     Document Type: Article

References (42)

1. Wen PY and Kesari S: Malignant gliomas in adults. N Engl J Med 359: 492-507, 2008.
2. Zhang J, Espinoza LA, Kinders RJ, et al: NANOG modulates stemness in human colorectal cancer. Oncogene: October 22, 2012 (Epub ahead of print). doi:10.1038/onc.2012.461.
3. Linderholm BK, Gruvberger-Saal S, Ferno M, et al: Vascular endothelial growth factor is a strong predictor of early distant recurrences in a prospective study of premenopausal women with lymph-node negative breast cancer. Breast 17: 484-491, 2008.
4. Ezeh UI, Turek PJ, Reijo RA, et al: Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. Cancer 104: 2255-2265, 2005. (Pubitemid 41579973)
5. Bourguignon LY, Peyrollier K, Xia W and Gilad E: Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem 283: 17635-17651, 2008.
6. You JS, Kang JK, Seo DW, et al: Depletion of embryonic stem cell signature by histone deacetylase inhibitor in NCCIT cells: involvement of Nanog suppression. Cancer Res 69: 5716-5725, 2009.
7. Niu CS, Li DX, Liu YH, et al: Expression of NANOG in human gliomas and its relationship with undifferentiated glioma cells. Oncol Rep 26: 593-601, 2011.
8. Ranganathan R, Lu KP, Hunter T and Noel JP: Structural and functional analysis of the mitotic rotamase Pin1 suggests substrate recognition is phosphorylation dependent. Cell 89: 875-886, 1997. (Pubitemid 27513514)
9. Shen M, Stukenberg PT, Kirschner MW and Lu KP: The essential mitotic peptidyl-prolyl isomerase Pin1 binds and regulates mitosis-- specific phosphoproteins. Genes Dev 12: 706-720, 1998. (Pubitemid 28134302)
10. Lam PB, Burga LN and Wu BP: Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability. Mol Cancer 7: 91, 2008.
11. Kuramochi J, Arai T and Ikeda S: High Pin1 expression is associated with tumor progression in colorectal cancer. J Surg Oncol 94: 155-160, 2006. (Pubitemid 44267198)
12. Ryo A, Hirai A and Nishi M: A suppressive role of the prolyl isomerase Pin1 in cellular apoptosis mediated by the death-associated protein Daxx. J Biol Chem 282: 36671-36681, 2007.
13. Moretto-Zita M, Jin H and Shen Z: Phosphorylation stabilizes Nanog by promoting its interaction with Pin1. Proc Natl Acad Sci USA 107: 13312-13317, 2010.
14. He H, Niu CS and Li MW: Correlation between glioblastoma stem-like cells and tumor vascularization. Oncol Rep 27: 45-50, 2012.
15. Sotomayor P, Godoy A, Smith GJ and Huss WJ: Oct4A is expressed by a subpopulation of prostate neuroendocrine cells. Prostate 69: 401-410, 2009.
16. Ayala G, Wang D, Wulf G, et al: The prolyl isomerase Pinl is a novel prognostic marker in human prostate cancer. Cancer Res 63: 6244-6251, 2003. (Pubitemid 37255170)
17. Bao L, Kimzey A, Sauter G, et al: Prevalent overexpression of prolyl isomerase Pinl in human cancers. Am J Pathol 164: 1727-1737, 2004. (Pubitemid 38529775)
18. Sasaki T, Ryo A, Uemura H, et al: An immunohistochemical scoring system of prolyl isomerase Pin1 for predicting relapse of prostate carcinoma after radical prostatectomy. Pathol Res Pract 202: 357-364, 2006.
19. Van Meir EG, Hadjipanayis CG, Norden AD, et al: Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 60: 166-193, 2010.
20. Lu KP and Zhou XZ: The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. Nat Rev Mol Cell Biol 8: 904-916, 2007. (Pubitemid 47622559)
21. Saegusa M, Hashimura M and Kuwata T: Pin1 acts as a modulator of cell proliferation through alteration in NF-kappaB but not β-catenin/TCF4 signalling in a subset of endometrial carcinoma cells. J Pathol 222: 410-420, 2010.
22. Luo Z, Wijeweera A, Oh Y, et al: Pin1 facilitates the phosphorylation-dependent ubiquitination of SF-1 to regulate gonadotropin β-subunit gene transcription. Mol Cell Biol 30: 745-763, 2010.
23. Nakano A, Koinuma D, Miyazawa K, et al: Pin1 down-regulates transforming growth factor-β (TGF-β) signaling by inducing degradation of Smad proteins. J Biol Chem 284: 6109-6115, 2009.
24. Siepe D and Jentsch S: Prolyl isomerase Pin1 acts as a switch to control the degree of substrate ubiquitylation. Nat Cell Biol 11: 967-972, 2009.
25. Nicole Tsang YH, Wu XW, Lim JS, et al: Prolyl isomerase Pin1 downregulates tumor suppressor RUNX3 in breast cancer. Oncogene 32: 1488-1496, 2012.
26. Mei PJ, Bai J, Liu H, et al: RUNX3 expression is lost in glioma and its restoration causes drastic suppression of tumor invasion and migration. J Cancer Res Clin Oncol 137: 1823-1830, 2011.
27. Mueller W, Nutt CL, Ehrich M, et al: Downregulation of RUNX3 and TES by hypermethylation in glioblastoma. Oncogene 26: 583-593, 2007. (Pubitemid 46160971)
28. Akhoondi S, Sun D, von der Lehr N, et al: FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res 67: 9006-9012, 2007. (Pubitemid 47535882)
29. Maser RS, Choudhury B, Campbell PJ, et al: Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 447: 966-971, 2007. (Pubitemid 46975753)
30. Strohmaier H, Spruck CH, Kaiser P, et al: Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 413: 316-322, 2001. (Pubitemid 32905853)
31. Min SH, Lau AW, Lee TH, et al: Negative regulation of the stability and tumor suppressor function of Fbw7 by the Pin1 prolyl isomerase. Mol Cell 46: 771-783, 2012.
32. Ryo A, Liou YC, Lu KP, et al: Prolyl isomerase Pin1: a catalyst for oncogenesis and a potential therapeutic target in cancer. J Cell Sci 116: 773-783, 2003. (Pubitemid 36367627)
33. Mitsui K, Tokuzawa Y, Itoh H, et al: The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 113: 631-642, 2003. (Pubitemid 36694188)
34. Pan G and Thomson JA: Nanog and transcriptional networks in embryonic stem cell pluripotency. Cell Res 17: 42- 49, 2007.
35. Pereira L, Yi F and Merrill BJ: Repression of Nanog gene transcription by Tcf3 limits embryonic stem cell self-renewal. Mol Cell Biol 26: 7479-7491, 2006. (Pubitemid 44547699)
36. Suzuki A, Raya A, Kawakami Y, et al : Maintenance of embryonic stem cell pluripotency by Nanog-mediated reversal of mesoderm specification. Nat Clin Pract Cardiovasc Med 3: 114-122, 2006.
37. Siu MK, Wong ES, Kong DS, et al: Stem cell transcription factor NANOG controls cell migration and invasion via dysregulation of E-cadherin and FoxJ1 and contributes to adverse clinical outcome in ovarian cancers. Oncogene: September 3, 2012 (Epub ahead of print). doi:10.1038/onc.2012.363 2012.
38. Singh SK, Clarke ID, Terasaki M, et al: Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828, 2003. (Pubitemid 37187480)
39. Huff CA, Matsui W, Smith BD and Jones RJ: The paradox of response and survivalin cancer therapeutics. Blood 107: 431-434, 2006. (Pubitemid 43076361)
40. Yang L, Zhang X, Zhang M, et al: Increased nanog expression promotes tumor development and Cisplatin resistance in human esophageal cancer cells. Cell Physiol Biochem 30: 943-952, 2012.
41. Ye F, Zhou C, Cheng Q, et al: Stem-cell-abundant proteins Nanog, Nucleostemin and Musashi1 are highly expressed in malignant cervical epithelial cells. BMC Cancer 8: 108, 2008.
42. Guo Y, Liu S, Wang P, et al: Expression profile of embryonic stem cell-associated genes Oct4, Sox2 and Nanog in human gliomas. Histopathology 59: 763-775, 2011.